首页> 中文期刊>中国医药导报 >白三烯受体拮抗剂治疗咳嗽变异性哮喘临床观察

白三烯受体拮抗剂治疗咳嗽变异性哮喘临床观察

     

摘要

Objective: To investigate clinical efficacy of leukotriene receptor antagonist in the treatment of cough variant asthma. Methods: From April 2008 to April 2010 312 cases of out-patient children with cough variant asthma were selected and divided into hormone inhalation group (152 cases) and leukotriene receptor antagonist group (160 cases), relief time of clinical symptom and recurrence were observed, clinical efficacy was evaluated. Results: The total effective rate had significant difference between two groups (P<0.05); relief time of clinical symptom and recurrence had no significant difference between two groups (P>0.05). Conclusion: Clinical efficacy of leukotriene receptor antagonist in the treatment of cough variant asthma is exact, improves symptoms obviously and prevents relapse, side effects decreases, compliance is good.%目的:探讨白三烯受体拮抗剂治疗咳嗽变异性哮喘临床疗效.方法:将2008年4月-2010年4月门诊收治的312例咳嗽变异性哮喘儿童分为激素吸入组152例,白三烯受体拮抗组160例,观察两组临床症状缓解时间、复发情况、临床疗效评价.结果:两组总有效率比较.差异有统计学意义(P<0.05);两组临床症状缓解时间、复发情况比较,差异无统计学意义(P>0.05).结论:白三烯受体拮抗剂治疗咳嗽变异性哮喘临床疗效确切,改善控制症状明显,可防止复发,副作用小,顺应性良好.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号